NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Price Target & More

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals announced that its board has approved a share repurchase program on Thursday, August 10th 2017, which authorizes the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 13.3% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's management believes its stock is undervalued.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) issued its quarterly earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported $0.53 EPS for the quarter, missing the Zacks' consensus estimate of $0.68 by $0.15. The specialty pharmaceutical company earned $46.60 million during the quarter, compared to analysts' expectations of $48.88 million. Eagle Pharmaceuticals had a return on equity of 21.89% and a net margin of 15.32%. The business's revenue was down 39.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.42 earnings per share. View Eagle Pharmaceuticals' Earnings History.

4 equities research analysts have issued 1 year price objectives for Eagle Pharmaceuticals' stock. Their forecasts range from $54.00 to $81.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $71.25 in the next year. This suggests that the stock has a possible downside of 15.2%. View Analyst Ratings for Eagle Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Eagle Pharmaceuticals include Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), Amicus Therapeutics (FOLD), The Medicines (MDCO), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN) and Intercept Pharmaceuticals (ICPT).

Media stories about EGRX stock have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Eagle Pharmaceuticals earned a daily sentiment score of 0.18 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 44.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Eagle Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.14%), Hartford Investment Management Co. (0.05%), Louisiana State Employees Retirement System (0.02%) and Municipal Employees Retirement System of Michigan (0.02%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Eagle Pharmaceuticals.

EGRX stock was acquired by a variety of institutional investors in the last quarter, including Hartford Investment Management Co. and Louisiana State Employees Retirement System. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EGRX stock can currently be purchased for approximately $84.00.

Eagle Pharmaceuticals has a market capitalization of $1.22 billion and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]